Trial reportInternational journal of impotence research
Analysis of the therapeutic effect of tadalafil on male ED after transurethral resection of prostate.
Trial report in International journal of impotence research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 5 citations in OpenAlex.
- The effect of tadalafil 5 mg on erection and persistent storage lower urinary tract symptoms after transurethral resection of prostate: a randomized controlled study.Basic and clinical andrology · 2025Article
- The volume of prostate can impact the male sexual function following photoselective vaporization of the prostate: results of a prospective analysis of 128 patients with 2-year follow-up.International urology and nephrology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of this study is to explore the therapeutic effect of Tadalafil on male ED after transurethral resection of prostate (TURP). Using the 5-item version of the International Index of Erectile Function (IIEF-5), ED was assessed in 104 male patients who experienced ED after TURP. These patients were assigned randomly into the therapy group and matched group on the basis of the degree of ED. The patients of the therapy group received Tadalafil, and the patients of matched group received placebo of starch. According to their actual conditions, all patients were informed of the action mechanism and administration of Tadalafil in detail, and advised to use the drug 1 h before sexual activity as recommended. The dose was increased from 10 to 20 mg by week 2 and 4, depending on the effects and adverse reactions. After 8 weeks, ED was re-assessed by IIEF-5. In therapy group, ED was cured in 28 cases, improved in 17 cases, and nonresponsive in 7 cases, with an overall effective rate of 86.5%. In matched group, ED was cured in 6 cases, improved in 7 cases, and non-responsive in 39 cases, with an overall effective rate of 25%. The statistical difference was significant (P<0.05). No significant adverse reaction was observed in any patient. In conclusion, Tadalafil is safe and effective, and can be used as the first-line medication for the clinical treatment of post-TURP ED.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.